Adjuvant formulation for veterinary vaccines: Montanide™ Gel safety profile

Procedia in Vaccinology

Volumn 1, Issue 1, 2009, Pages 140-147

  Parker, R ^a   Deville, S ^b   Dupuis, L ^b   Bertrand, F ^b   Aucouturier, J ^b  

^a SEPPIC Inc 30   (United States)

^b SEPPIC Tour Kupka C   (France)

Author keywords

Adjuvant; Bordetella bronchiseptica; Montanide gel; Pasteurella multocida; Polymer; Safety; Veterinary vaccine

Indexed keywords

ALUMINUM; IMMUNOLOGICAL ADJUVANT; MONTANIDE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CATTLE; CONTROLLED STUDY; DOG; DRUG FORMULATION; DRUG SAFETY; FEMALE; GEL; INJECTION SITE; MALE; NONHUMAN; PRIORITY JOURNAL; SWINE; VACCINATION;

EID: 71549136154     PISSN: 1877282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.provac.2009.07.026     Document Type: Article

References (18)

1. Murphy D., Corner L.A., and Gormley E. Adverse reactions to Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccination against tuberculosis in humans, veterinary animals and wildlife species. Tuberculosis (Edinb). 88 4 (2008 Jul) 344-357 Epub 2008 Jan 28. Review
2. Cox J.C., and Coulter A.R. Adjuvants: a classification and review of their mode of action. Vaccine 15 (1997) 248-256
3. Audibert A.C., and Lise L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 14 6 (1993 Jun) 281-284 Review
4. Lindblad E.B. Aluminium adjuvants--in retrospect and prospect. Vaccine 22 27-28 (2004 Sep 9) 3658-3668 Review
5. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20 Suppl. 3 (2002) S34-S39
6. Ulanova M., Tarkowski A., Hahn-Zoric M., and Hanson L.A. The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 69 2 (2001) 1151-1159
7. Rimaniol A.C., Gras G., Verdier F., Capel F., Grigoriev V.B., Porcheray F., et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22 23/24 (2004) 3127-3135
8. Cloete M., Dungu B., Van Staden L.I., Ismail-Cassim N., and Vosloo W. Evaluation of different adjuvants for foot-and-mouth disease vaccine containing all the SAT serotypes Onderstepoort. J Vet Res. 75 1 (2008 Mar) 17-31
9. Hendrick M.J., Goldschmidt M.H., Shofer F.S., Wang Y.-Y., and Somlyo A.P. Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Res 52 (1992) 5391-5394
10. Verdier F., Burnett R., Michelet-Habchi C., Moretto P., Fievet-Groyne F., and Sauzeat E. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine 23 11 (2005 Feb 3) 1359-1367
11. Bahnemann H.G., and Mesquita J.A. Oil adjuvant vaccine against foot-and---mouth disease. Bol. Centr. Panam. Fiebre Aftosa 53 (1987) 25-30
12. Jansen T., Hofmans M.P., Theelen M.J., and Schijns V.E. Structure-activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses. Vaccine 23 8 (2005 Jan 11) 1053-1560
13. Oda K., Tsukahara F., Kubota S., Kida K., Kitajima T., and Hashimoto S. Emulsifier content and side effect of oil-based adjuvant vaccine in swine. Research in Veterinary Science 81 (2006) 51-57
14. Aucouturier J., Deville S., Perret C., Vallée I., and Boireau P. Assessment of efficacy and safety of various adjuvant formulations with a total soluble extract of Trichinella spiralis. Parasite 8 2 Suppl (2001 Jun) S126-S132
15. Dupuis L, Deville S, Bertrand F, Laval A, Aucouturier J. Adjuvant formulation for multivalent pig vaccines: Pasteurella multocida anatoxins and inactivated Bordetella bronchiseptica, Montanide™ Gel safety study. Proceedings of the International pig veterinary society 2008, Durban.
16. Van Amersfoot E.S., Van Berkel T.J.C., and Kuiper J. Receptors, Mediators, and mechanism involved in bacterial sepssis and spetic shock. Clin. Microbiol. Rev. (2003 July) 379-414
17. Deville S, Parker R, Laval A. Adjuvant formulation for Influenza H1N1 and H3N2 pig vaccines: Montanide™ Gel safety and efficacy study. Proceedings of the Conference of Research of Workers in Animal Diseases 2008, Chicago.
18. Day M.J., Schoon H.A., Magnol J.P., Saik J., Devauchelle P., Truyen U., Gruffydd-Jones T.J., Cozette V., Jas D., Poulet H., Pollmeier M., and Thibault J.C. A kinetic study of histopathological changes in the subcutis of cats injected with non-adjuvanted and adjuvanted multi-component vaccines. Vaccine 25 20 (2007 May 16) 4073-4084